440 related articles for article (PubMed ID: 23380829)
21. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
22. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
24. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.
Asselin BL
Adv Exp Med Biol; 1999; 457():621-9. PubMed ID: 10500842
[TBL] [Abstract][Full Text] [Related]
25. Comparative pharmacokinetic studies of three asparaginase preparations.
Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
27. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
28. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
30. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
Maese L; Loh ML; Choi MR; Lin T; Aoki E; Zanette M; Agarwal S; Iannone R; Silverman JA; Silverman LB; Raetz EA; Rau RE
Blood; 2023 Feb; 141(7):704-712. PubMed ID: 36108304
[TBL] [Abstract][Full Text] [Related]
31. [Update on L-asparaginase treatment in paediatrics].
Moscardó Guilleme C; Fernández Delgado R; Sevilla Navarro J; Astigarraga Aguirre I; Rives Solà S; Sánchez de Toledo Codina J; Fuster Soler JL; Parra Ramirez L; Molina Garicaño J; González Martínez B; Madero López L
An Pediatr (Barc); 2013 Nov; 79(5):329.e1-329.e11. PubMed ID: 23727426
[TBL] [Abstract][Full Text] [Related]
32. Production of a novel N-terminal PEGylated crisantaspase.
Torres-Obreque K; Meneguetti GP; Custódio D; Monteiro G; Pessoa-Junior A; de Oliveira Rangel-Yagui C
Biotechnol Appl Biochem; 2019 May; 66(3):281-289. PubMed ID: 30597637
[TBL] [Abstract][Full Text] [Related]
33. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
Sikorska-Fic B; Makowska K; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
[TBL] [Abstract][Full Text] [Related]
34. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
[TBL] [Abstract][Full Text] [Related]
35. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
Müller HJ; Löning L; Horn A; Schwabe D; Gunkel M; Schrappe M; von Schütz V; Henze G; Casimiro da Palma J; Ritter J; Pinheiro JP; Winkelhorst M; Boos J
Br J Haematol; 2000 Aug; 110(2):379-84. PubMed ID: 10971395
[TBL] [Abstract][Full Text] [Related]
36. A desensitization protocol in children with L-asparaginase hypersensitivity.
Akbayram S; Doğan M; Akgün C; Caksen H; Oner AF
J Pediatr Hematol Oncol; 2010 Jul; 32(5):e187-91. PubMed ID: 20505537
[TBL] [Abstract][Full Text] [Related]
37. Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase
Tong WH; Rizzari C
Haematologica; 2023 Oct; 108(10):2606-2615. PubMed ID: 37470157
[TBL] [Abstract][Full Text] [Related]
38. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Wacker P; Land VJ; Camitta BM; Kurtzberg J; Pullen J; Harris MB; Shuster JJ;
J Pediatr Hematol Oncol; 2007 Sep; 29(9):627-32. PubMed ID: 17805038
[TBL] [Abstract][Full Text] [Related]
39. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
Sandley M; Angus J
Leuk Lymphoma; 2023 Apr; 64(4):776-787. PubMed ID: 36781296
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.
Matteo C; Colombini A; Bettini LR; Porcu L; Barzaghi S; Ceruti T; Silvestri D; Amoroso A; Dell'Acqua F; Gotti G; Nastasi C; Zucchetti M; Rizzari C
Pediatr Blood Cancer; 2022 Sep; 69(9):e29753. PubMed ID: 35561075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]